Zentalis Pharmaceuticals, Inc. (ZNTL)
Nasdaq · Healthcare · Biotechnology
$2.78+10.32%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $273M
- 52-week range
- $1.21 – $6.95
- 52-week change
- +62.58%
- EPS (trailing)
- −$1.96
- Analyst rating
- 1.8 Buy
- Next earnings
- Nov 10, 2026
Fiscal year to Dec 2025
- Revenue
- $0K (−100.00%)
- Net income
- −$137M
- Diluted EPS
- −$1.91
- Free cash flow
- −$125M
From the company’s annual report on SEC EDGAR.
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Headquarters: San Diego, United States · 106 employees · zentalis.com